Logo Logo
Hilfe
Hilfe
Switch Language to English

Höllerhage, Matthias; Möbius, Claudia; Melms, Johannes; Chiu, Wei-Hua; Goebel, Joachim N.; Chakroun, Tasnim; Köglsperger, Thomas; Örtel, Wolfgang H.; Rösler, Thomas W.; Bickle, Marc und Höglinger, Günter U. (2017): Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. In: Scientific Reports, Bd. 7, 11469 [PDF, 6MB]

Abstract

alpha-synuclein-induced neurotoxicity is a core pathogenic event in neurodegenerative synucleinopathies such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. There is currently no disease-modifying therapy available for these diseases. We screened 1,600 FDA-approved drugs for their efficacy to protect LUHMES cells from degeneration induced by wild-type alpha-synuclein and identified dipyridamole, a non-selective phosphodiesterase inhibitor, as top hit. Systematic analysis of other phosphodiesterase inhibitors identified a specific phosphodiesterase 1 inhibitor as most potent to rescue from alpha-synuclein toxicity. Protection was mediated by an increase of cGMP and associated with the reduction of a specific alpha-synuclein oligomeric species. RNA interference experiments confirmed PDE1A and to a smaller extent PDE1C as molecular targets accounting for the protective efficacy. PDE1 inhibition also rescued dopaminergic neurons from wild-type alpha-synuclein induced degeneration in the substantia nigra of mice. In conclusion, this work identifies inhibition of PDE1A in particular as promising target for neuroprotective treatment of synucleinopathies.

Dokument bearbeiten Dokument bearbeiten